THE EFFECT OF SGLT2 INHIBITORS ON COGNITIVE FUNCTION IN PATIENTS WITH TYPE 2 DIABETES

Аннотация

Type 2 diabetes mellitus (T2DM) is associated with an increased risk of developing cognitive impairments, including dementia. In recent years, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have gained popularity as antidiabetic agents with potential neuroprotective effects. SGLT2 inhibitors have demonstrated potential benefits beyond improving cardiac and renal function, particularly in the prevention and treatment of cognitive impairments (CI), including mild cognitive impairment, Alzheimer’s disease, and vascular dementia in patients with T2DM. Research suggests that SGLT2i may improve diabetic-related cognitive impairments through mechanisms involving metabolism, inflammation, oxidative stress, neurotrophic factors, and acetylcholinesterase (AChE) inhibition. This article is dedicated to analyzing the data on the impact of SGLT2 inhibitors on cognitive function in patients with T2DM. The literature review highlights the potential of these agents in reducing the risk of neurodegeneration and stabilizing cognitive status; however, further large-scale clinical studies are needed.